RSS Feeds
Montelukast-Induced Hepatitis
- Marc F. Goldstein, MD;
- James Anoia, MD; and
- Martin Black, MD
- From Drexel University College of Medicine and Temple University School of Medicine, Philadelphia, PA.
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
TO THE EDITOR:
Background: Leukotriene modifiers, commonly used for persistent asthma, are usually well tolerated. Although reports have described elevated liver enzyme levels, hepatitis, and fulminant hepatic failure induced by zafirlukast (1-9) and zileuton (8), clinical trials of montelukast have revealed no liver toxicity (9). We describe a patient who developed acute hepatitis while receiving montelukast. Discontinuing montelukast therapy led to normalization of all liver function test results except for persistently elevated aminotransferase levels. …
